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INTRODUCTION
The use of specific chemicals to prevent the development
or retard the progression of carcinogenesis, a technique known
as chemoprevention, offers a promising strategy for cancer
prevention (1, 2). Cancer chemoprotective potential of natu-
rally occurring phytochemicals in food or medicinal plants
continues to be a major area of scientific interest (3, 4). Gin-
seng has been used for several thousand years in the Orient
as a tonic, adaptogenic, anti-aging, prophylactic and restora-
tive remedy. More recently, it has been reported that gin-
seng has cancer chemopreventive activity (5).
Several studies have shown that some preparations of gin-
seng inhibit carcinogenesis in animal models. Korean red
ginseng extract decreased lung adenoma incidence induced
by urethane or aflatoxin B1, diminished the average diame-
ter of lung adenoma and the incidence of diffuse pulmonary
infiltration induced by 9,10-dimethyl-1,2-benzanthracene
(DMBA), and also decreased the incidence of hepatoma in-
duced by aflatoxin B1 in newborn mice (6). In Yun’ s anti-
carcinogenicity test (9 week medium term bioassay model)
powders of 6-yr-dried fresh ginseng, 5 and 6 yr-white gin-
seng, and 4, 5 and 6 yr-red ginseng significantly decreased
the incidence of lung adenoma induced by benzo(a)pyrene
in newborn N:GP (S) mice (7). In the same mouse model a
statistically significant anticarcinogenic effect was observed
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Chemoprevention of Mammary, Cervix and Nervous system
Carcinogenesis in Animals using Cultured Panax ginseng Drugs and
Preliminary Clinical Trials in Patients with Precancerous Lesions of
the Esophagus and Endometrium
The anticarcinogenic effects and mechanisms of the biotechnological drugs of
Panax ginseng C.A. Meyer cultivated in Russia, bioginseng, panaxel and panax-
el-5, were studied. Bioginseng was produced from a tissue culture of ginseng
root cultured on standard medium, whereas panaxel and panaxel-5 were pro-
duced from ginseng tissue root cultures using standard mediums enriched with
2-carboxyethylgermanium sesquioxide and 1-hydroxygermatran-monohydrate
respectively. All three ginseng drugs inhibited the development of mammary
tumors induced by intramammary injections of N-methyl-N-nitrosourea (MNU) in
rats, the development of the brain and spinal cord tumors induced by transpla-
cental administration of N-ethyl-N-nitrosourea (ENU) in rats, and the develop-
ment of uterine, cervical and vaginal tumors induced by intravaginal applications
of 7,12-dimethylbenz(a)anthracene (DMBA) in mice. The ginseng drugs induced
the cytotoxic activity of macrophages in mice, enhanced T-lymphocyte rosette
formation in guinea pigs exposed to cyclophosphamide, and stimulated the pro-
duction of thyroid hormones in rats. These mechanisms may contribute to the
anticarcinogenic action of the ginseng drugs. The organic germanium compounds
present in panaxel and panaxel-5 did not potentiate the anticarcinogenic or im-
muno-stimulatory effects as much as biogeinseng. Preliminary clinical trials with
panaxel and bioginseng were carried out in patients with precancerous lesions
of the esophagus and endometrium. Panaxel was found to have a strong thera-
peutic effect in patients suffering from chronic erosive esophagitis. Bioginseng
induced the regression of adenomatous-cystic hyperplasia of the endometrium
in some patients. Thus, we conclude that the drugs of ginseng appear to hold
considerable promise for future cancer chemoprevention.
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Chemopreventionin extracts of 6 yr-dried fresh ginseng, 6 yr-white ginseng,
and 4, 5 and 6 yr-red ginseng (8). Moreover, a water extract
of red ginseng inhibited lung tumor incidence induced by
benzo(a)pyrene in newborn N:GP (S) mice (9), and the
ethanol-insoluble fraction of the water extract of Panax gin-
seng inhibited lung tumor incidence induced by benzo(a)
pyrene in newborn N:GP (S) mice (10). In addition, extract
of the roots of Panax notoginseng exhibited anti-tumor-pro-
moting activity in a model of the lung carcinogenesis in-
duced by 4-nitroquinoline-N-oxide and glycerol in mice
(11). Ginseng extract also inhibited the gastric carcinogene-
sis induced by N-methyl-N′ -nitro-N-nitrosoguanidine in
rats (12), and Panax notoginseng extract inhibited liver cancer
development induced by N-nitrosodiethylamine in rats (13).
A saponin, majonoside-R2, isolated from the rhizomes and
roots of Panax vietnamensis exhibited potent anti-tumor-pro-
moting activity in a two-stage carcinogenic test of mouse
hepatic tumor using N-nitrosodiethylamine as an initiator
and phenobarbital as a promoter (14). In a two-stage model,
red ginseng extracts inhibited DMBA and croton oil-in-
duced skin papilloma in mice (15). The extract of the roots
of Panax notoginseng exhibited anti-tumor-promoting activi-
ty in the two-stage carcinogenesis of mouse skin tumors in-
duced by DMBA as an initiator and a mycotoxin or fumon-
isin B1 as promoter. This extract exhibited anti-tumor-ini-
tiating activity on skin tumors induced by a nitric oxide
donor as an initiator and 12-o-tetradecanoylphorbol-13-
acetate (TPA) as a promoter (16). Topical application of the
methanol extract of Panax ginseng onto mouse skin 10 min
prior to TPA, significantly ameliorated skin papillomagene-
sis initiated by DMBA (17). The saponin, majonoside-R2,
rendered anti-tumor-promoting activity in a two-stage car-
cinogenic tests of mouse skin using DMBA as an initiator
and TPA or fumonisin B1 as a promoter (18). In vitro, the
root extract of Panax ginseng exerted an inhibitory effect on
the transformation of NIH 3T3 cells initiated by 3-methyl-
cholanthrene, methyl methanesulfonate or 1-methyl-3-nitro-
1-nitrosoguanidine (19), and the extract of the roots of
Panax notoginseng (11) and a saponin, majonoside-R2, (18)
inhibited the early antigen activation of Epstein-Barr virus
induced by TPA in Raji cells.
Several epidemiological studies on ginseng intake and
cancer risk have been conducted in the Korea Cancer Center
Hospital, Seoul. In a case-control study involving interview-
ing 905 pairs of cases and controls, ginseng consumers were
found to have a lower risk (odds ratio was 0.56) of cancer
that ginseng non-consumers (20). Later, Yun et al. extended
the number of subjects in a case-controlled study involving
1987 pairs, and showed that increased frequency and dura-
tion of ginseng intake decreased the risk of cancer in a dose-
dependent manner, and that ginseng consumers had a lower
risk for most cancers than non-consumers; these included,
cancers of the lip, oral cavity, pharynx, larynx, esophagus,
stomach, colon and rectum, liver, pancreas, lung and ovaries
(21). The same authors performed a more reliable cohort
study in 4634 people over 40 yr old, and showed that gin-
seng consumers had a lower cancer risk (odds ratio 0.40)
than non-consumers, especially for gastric and lung cancers
(22).
In the present study, we examined and compared the anti-
carcinogenic effects of three biotechnological drugs obtained
from Panax ginseng C.A. Meyer in mammary, nervous sys-
tem and cervix animal tumor models induced by chemical
carcinogens. We also investigated the immunological and
hormonal mechanisms of the ginseng drugs. Preliminary
clinical trials of the drugs were also carried out in patients
with chronic erosive esophagitis and hyperplasia of the
endometrium using the dynamics of precancerous lesions of
the esophagus and endometrium as end points.
MATERIALS AND METHODS
Chemicals and ginseng drugs
Carcinogens, N-methyl-N-nitrosourea (MNU), N-ethyl-
N-nitrosourea (ENU) and 7,12-dimethylbenz(a)anthracene
(DMBA), were obtained from Sigma Chemical Co. (St. Louis,
MO, U.S.A.). Ginseng drugs were purchased from Kirishi’ s
Biochemical Factory (Lenigrad region, Russia). It was stud-
ied three biotechnological drugs of ginseng root (Panax gin-
seng C.A. Meyer cultivated in Russia), bioginseng, panaxel
and panaxel-5 were studied. Bioginseng was produced from
a tissue culture of the strain of Panax ginseng root cultured
in standard medium, which was a modification of the regu-
lar medium described by Murashige and Skoog (23). Panax-
el and panaxel-5 were produced from tissue cultures of the
root cultures of the Panax ginseng strain in a standard media
enriched with organic germanium compounds, such as 2-
carboxyethylgermanium sesquioxide (Ge-132) and 1-hydrox-
ygermatran-monohydrate (23). Bioginseng (24) and panaxel
(25) are officinal medicinal drugs. The ginseng drugs used
were ethanol extracts of the biomasses of the tissue cultures.
The contents of glycosides in bioginseng, panaxel and panax-
el-5 were >1.1, >2.2 and >2.5% of the whole alcohol tinc-
tures, respectively. The germanium content of panaxel and
panaxel-5 was 10×10-3 and 2.2×10-3 mg % to ash respec-
tively. More detailed characteristics of the ginseng drugs
used in this study have been described elsewhere (26). In
experiments, prior to application, alcohol was removed from
the ginseng tinctures with a vacuum evaporator, and water
was added to the residue to the volume of the initial tinc-
ture. In clinical studies, patients were given ginseng drugs
as alcohol tinctures.
Animals
Outbred albino LIO rats from the Animal Department of
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burg, and outbred albino SHR mice from the Rappolovo
Animal Breeding Farm of the Russian Academy of Medical
Sciences, Leningrad region, Russia, were used for the study.
The characteristics of these rats (27) and mice (28) have been
described elsewhere. LIO rats from the Animal Department
of the N.N. Petrov Research Institute of Oncology, mice
C57Bl and guinea pigs from the Rappolovo Animal Breed-
ing Farm were used in experiments on immunological and
hormonal mechanisms. Animals were housed in steel and
polypropylene cages, 4-8 animals in each, under a 14 hr/10
hr light/dark regimen at 22±2℃, and received standard
laboratory chow and tap water ad libitum.
Anticarcinogenic experiments
Mammary carcinogenesis 
A model of tumor induction of the mammary gland involv-
ing intramammary injections of MNU in rats was used (29).
Female LIO 2 month old rats were treated with a single
intramammary injection of 1 mg of MNU, dissolved in 0.1
mL saline, per gland into the tissue of all 12 mammary
glands. One week after the treatment the rats were random-
ized and divided into 4 groups. In groups 2, 3 and 4, rats
were treated with bioginseng, panaxel or panaxel-5, respec-
tively. The ginseng drugs were given perorally by gavage at
0.5 mL/rat (2.5 mL/kg body weight) for five consecutive days
per week for 27 weeks. In group 1 (controls), water was given
similarly perorally by gavage at 0.5 mL/rat. Group 5 (intact
controls) served as untreated controls. All surviving animals
were sacrificed 28 weeks after the beginning of the experi-
ment.
Transplacental carcinogenesis
A model of induction of tumors of the nervous system and
kidney involved the transplacental administration of ENU
in rats (30). Pregnant LIO rats, 3-4 months old, were given
a single intravenous injection of ENU (75 mg/kg body
weight) dissolved in saline, on the 21st day after concep-
tion. Their descendants of both sexes were randomized and
divided into four groups. In groups 2, 3, and 4 the rats were
treated with bioginseng, panaxel or panaxel-5, respectively,
perorally by gavage at 0.5 mL/rat (2.5 mL/kg body weight)
for five consecutive days, per week, starting at the age of
one month for 11 months. In group 1 (control), water was
given similarly perorally by gavage at 0.5 mL/rat during
their postnatal life. Group 5 (intact controls), descendants
of both sexes were obtained from the intact pregnant rats
but were not subjected to any treatment during their post-
natal life. All surviving offspring were sacrificed 12 months
after birth.
Uterine cervix carcinogenesis
The model of tumor induction of  the uterine cervix and
vagina in mice involved intravaginal applications of DMBA
(29). Female SHR mice, 2 months old, were subjected to
intravaginal applications of polyurethane tampons soaked
with a solution of 0.1% DMBA in triethylene glycol twice a
week for 6 weeks (total dose 300 mkg of DMBA per mouse).
After administering the carcinogen, the mice were random-
ized and divided into eight groups. In the case of groups 1,
2, 3 and 4, the mice were given perorally by gavage, water
(control), bioginseng, panaxel or panaxel-5 respectively, at
0.15 mL/mouse (7.5 mL/kg body weight) for five consecu-
tive days weekly over 38 weeks. Groups 5, 6, 7 and 8, were
administered daily intravaginal applications of polyurethane
tampons soaked with either saline (control), bioginseng,
panaxel or panaxel-5 for 16 weeks. The doses of the ginseng
drugs were 30  L per application. In the group 9 (intact
control), the female mice were not exposed to any treatment
and served as untreated controls. All surviving mice of the
groups 1-4 and 9 were sacrificed 44 weeks after the begin-
ning of experiment. Mice of groups 5-8 were sacrificed 22
weeks after the beginning of the experiment.
Pathological investigation
All animals sacrificed or found dead before the end of the
experiments were autopsied. Animals were killed using ether
steams. All tumors and other tissues with macroscopically
observed lesions were fixed in 10% neutral formalin, and
after routine histological treatment, were embedded in paraf-
fin. Sections (5-to 7-m thick) through the central part of
each tumor were stained with haematoxylin and eosin.
Neoplasms were classified according to the IARC recom-
mendations (31, 32).
Investigation of immunological mechanisms
The influence of the ginseng drugs on the cytotoxic and
growth-stimulating activities of macrophages was investi-
gated. Male C57Bl mice, 3 months old, were given peroral-
ly by gavage, water (control), bioginseng, panaxel or panax-
el-5 at 0.15 mL/mouse (7.5 mL/kg body weight) daily for 7
days. After the drug administration period, mice were sacri-
ficed and peritoneal macrophages were collected and pooled
from 3-5 animals. These were then incubated in vitro with
P3x-63-Ag/8 mouse myeloma cells. The cytotoxic and
growth-stimulating phases of macrophage activity were
determined as described elsewhere (33), and both of these
forms of functional macrophage activity in 5 independent
cultures were estimated by [H3] thymidine incorporation
into proliferating tumor target cells. Radioactivity was deter-
mined using a liquid scintillation counter Delta-300 (Nucle-
ar Chicago, U.S.A.).
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ty of T-system immunity was investigated. In pubertal male
guinea pigs with body weights of 250-300 g, T-immuno-
deficiency was induced with a single subcutaneous injection
of cyclophosphamide (Bristol-Myers Squibb, U.S.A.) at a
dose of 35 mg/kg of body weight. Thereafter the guinea pigs
were randomized and divided into 3 groups. In the control
group, the guinea pigs were given water, perorally by gav-
age at 1 mL daily for 7 days. In the other two groups, the
animals were given bioginseng or panaxel, perorally by gav-
age, at 5 mL/kg of body weight daily for 7 days. In the group
of intact controls, the guinea pigs were not subjected to any
treatment. The functional activity of T-system immunity
was estimated by the method of spontaneous T-cell rosette
formation (E-rosettes) of the guinea pig T-lymphocytes with
rabbit red blood cells, according to the method described
by Stadecker et al. (34).
Investigation of hormonal mechanisms
The influence of the ginseng drugs on hormonal status
was investigated in rats. Male LIO rats, 3 months old, were
given, perorally by gavage, water (control), bioginseng, panax-
el or panaxel-5 at 0.5 mL/rat (2.5 mL/kg body weight) daily
for 7 days. Thereafter, the level of hormones in blood plas-
ma were determined by standard radioimmunoassays. The
blood levels of corticotropin and aldosterone were deter-
mined using the ACTHK-PR and SB-ALDO-2 kits (ORIS,
France) respectively, according to the manufacturer’ s instruc-
tions. The level of corticosterone in blood was determined
using the RSL PAT Corticosterone (H3) KIT, RSL, U.S.A.
Similarly, the blood level of thyroid-stimulating hormone
was determined using the RIA-mat-TSH kit, Mallinkrodt
Diagnostica, Germany, and the blood levels of thyroxine
and tri-iodothyronine were estimated using the RIO-T4-
PG and RIO-T3-PG kits, Minsk, Byelorussia, respectively.
At the end of the mammary carcinogenic experiment, the
blood from several rats of all groups was collected, and the
blood plasma level of estradiol was determined by standard
radioimmunoassay using a CIA-TK kit, Sorin, Italy. Radioac-
tivity was determined with  - and  -counters (Beckman,
U.S.A.).
Clinical trials
Preliminary clinical trials of the ginseng drugs were car-
ried out in patients with precancerous lesions of the esopha-
gus and endometrium.
In one clinical study, 64 volunteers suffering from chronic
erosive esophagitis were recruited. The patients lived in a
region of the Republic of Uzbekistan where the incidence of
esophageal cancer and the prevalence of precancerous dis-
eases of the esophagus are elevated. The average age of the
patients was 36.5±3.4 yr, and there were 41 men and 23
women. The diagnosis of chronic erosive esophagitis was
established in the patients based on esophagoscopic exami-
nation data. The state of esophageal mucosa of each patient
was carefully documented on individual outpatient cards.
Inflammatory lesions and multiple erosions of the esophageal
mucosa were found in all patients. Erosions were localized
to the top third of the esophagus in 4 patients, to the medi-
al third of the esophagus in 15 patients, and simultaneously
to the medial and inferior thirds of the esophagus in 45 pa-
tients. Patients were given panaxel perorally at 50 drops 3
times every day (approximately 4 mL per day) for 1 month,
one course of treatment required approximately 120 mL of
the drug. Repeated esophagoscopic examinations were per-
formed 1 month after the start of treatment with panaxel. If
the state of esophageal mucosa had not improved as a result
of the first course of treatment, patients were given second
course of treatment of panaxel under a similar schema. Alto-
gether one, two or three courses of treatment with panaxel
were carried out in the patients, after each course of treat-
ment esophagoscopic examination was carried out in each
patient, and the endoscopic pattern of the esophageal mucosa
was carefully recorded on the individual’ s outpatient card.
The influence of panaxel on the endoscopic appearance of
the esophageal mucosa was estimated.
Nineteen control patients suffering from chronic erosive
esophagitis (12 men and 7 women; average age 38.2±5.3
yr) were also recruited. In all these patients, the inflamma-
tory lesions and multiple erosions of the esophageal mucosa
were also found during esophagoscopic examinations. The
erosions were localized at the top third of esophagus in 2
patients, at the medial third of the esophagus in 5 patients,
and  at both the medial and inferior thirds of the esophagus
in 12 patients. The control patients did not receive any treat-
ment. Repeated esophagoscopic examinations were performed
in all patients after 3 months, and the results of these were
carefully recorded on the individual outpatient cards.
In the other clinical study, 11 volunteers suffering from
hyperplasia of the endometrium were recruited. The aver-
age age of the patients was 42.3±3.5 yr, had regular men-
strual cycles, and diagnostic curettage of the uterine cavity.
Scrapings of the endometrium obtained after routine histo-
logical treatment were analyzed under the light microscope.
Based on the results of histopathological examinations, ade-
nomatous-cystic hyperplasia of the endometrium was diag-
nosed in 8 patients. Atypical hyperplasia of the endometri-
um was found in 3 patients. All patients were given biogin-
seng perorally at 30 drops 3 times every day (approximately
2.5 mL per day) over a period of 5-6 months (during 6 men-
strual cycles). During one course of treatment a patient con-
sumed about 400-450 mL of bioginseng tinctura. After the
completion of treatment, repeated diagnostic curettages of
the uterus cavity and histolpathological examination of the
endometrium were carried out in all patients.
As a control, 9 women with the endometrial hyperplasia
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ed. Diagnostic curettage of the uterus cavity and histologic
examination of the uterine mucosa were performed. Based
on the histopathological examinations, diagnosis of adeno-
matous-cystic hyperplasia of the endometrium was estab-
lished in 7 patients and atypical hyperplasia of the endometri-
um in 2 patients. The control patients were not given any
treatment, and repeated diagnostic curettages and histol-
pathological examinations of the uterine mucosa were car-
ried out after 5-6 months (after 6 menstrual cycles)
Statistics
Statistical analysis was performed using the chi-square test
and Student’ s t-test.
RESULTS
Anticarcinogenic experiments with the ginseng drugs
The results on the influence of ginseng drugs on MNU-
induced mammary carcinogenesis in rats are shown in Table
1. Intramammary injection of MNU induced tumors of the
mammary glands in 77.8% of rats, and the multiplicity of
tumors was 1.56 (group 1). The majority of the tumors were
adenocarcinomas and in a minority were fibroadenomas. In
22.2% of the animals, mesenchymal tumors of the kidney
were induced, which was apparently due to the carcinogenic
effect of MNU absorbed after intramammary injections (35).
In all the groups, unitary adenomas of the pituitary gland
and leukemias developed, which are characteristics of the
rat strain used (27) in terms of the spontaneous tumor back-
ground. All three ginseng drugs strongly inhibited the mam-
mary carcinogenesis induced by MNU in rats. Compared
with the MNU-only control group, bioginseng, panaxel,
and panaxel-5 (groups 2, 3 and 4) reduced the incidence of
the mammary tumors by 43.3%, 47.0% and 22.2%, respec-
tively, and their respective multiplicities by 62.2%, 60.3%
and 33.3%. Similarly, bioginseng, panaxel and panaxel-5
also decreased the incidence of the kidney tumors by 18.8%,
18.4% and 18.5%. In the intact control rats (group 5), the
tumors of the mammary gland and of the kidney were not
developed.
The results on the influences of the ginseng drugs on the
ENU-induced transplacental carcinogenesis in rats are pre-
sented in Table 2. Since there were no significant differences
between the male and female nervous system and kidney
tumor incidences, or between tumor incidences at other sites,
the data are presented irrespective of rat sex. ENU mostly
induced multiple tumors of the brain, spinal cord, peripher-
al nervous system and kidneys. Tumors of the peripheral
nervous system were mainly localized in the nervi trigemini
and rarely in the plexus lumbosacrarilylis, plexus brachialis,
radices of the spinal cord or other tissues. We have never
found nervous system tumors and kidney tumors develop-
ing spontaneously in the rat strain used in this experiment.
The incidences of spontaneous tumors of the pituitary gland,
mammary gland, ovaries, intestine, and leukemias (group
5) for the rat strain used have been reported before (27). In
comparison with the ENU-only control (group 1), the bio-
ginseng (group 2) showed a statistically significant decrease
in the total incidence and multiplicity of tumors, by 19.7%
and 43.1%, respectively. Moreover, bioginseng also signifi-
cantly decreased the multiplicity of tumors of the brain and
spinal cord by 48.2% and 52.5%, respectively. The anticar-
cinogenic effects of the germanium-contained drugs of gin-
seng were expressed slightly less evident. In comparison
with the ENU-only control group, panaxel (group 3) and
panaxel-5 (group 4) significantly decreased the total multi-
plicity of tumors by 33.0% and 28.3% respectively, and mul-
tiplicity of the brain tumors by 39.9% and 30.6% respec-
tively. In addition, panaxel also reduced the multiplicity of
kidney tumors by 55.6%. As a whole, the anticarcinogenic
effects of the ginseng drugs on transplacental carcinogenesis
can be judged as moderate, as shown primarily by the atti-
tude of tumors of the central nervous system.
The results on the influence of the ginseng drugs on
DMBA-induced uterine cervix and vagina carcinogenesis in
mice are presented in Table 3. In this carcinogenic model,
tumors propagate in the uterine cervix and vagina as a uni-
form conglomerate. Topical applications of DMBA induced
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Treatment Group
Number 
of rats Tumor incidence Number 
of tumors
Average number of
tumors/rat (Mean±SD)
Incidence of 
kidney tumorsb
Incidence of 
other tumors
c
1 MNU only, control 27 21 (77.8%) 42 1.56±0.19 6 (22.2%) 3 (11.1%)
2 MNU+bioginseng 29 10 (34.5%)d 17 0.59±0.14e 1 (3.4%)d 1 (3.4%)
3 MNU+panaxel 26 8 (30.8%)
d 16 0.62±0.26e 1 (3.8%)d 2 (7.7%)
4 MNU+panaxel-5 27 15 (55.6%) 28 1.04±0.15e 1 (3.7%)d 2 (7.4%)
5 Intact control 20 -- - - 2 (10.0%)
Table 1. Effects of the drugs of ginseng on the MNU-induced mammary carcinogenesis in female rats
aThe most of tumors are adenocarcinomas, a little of tumors are fibroadenomas; bMesenchymal tumors; cUnitary adenomas of pituitary gland and
leukemias; 
dStatistically significant (p<0.05-0.001) compared to the control group given MNU only by the chi-square test; eStatistically significant
(p<0.05-0.001) compared to the control group given MNU only by the Student’ s t-test.
Mammary tumors
atumors of the uterine cervix and vagina in 68.4% of mice,
and of 47.4% were carcinomas and 21.1% were papillomas
in group 1. Tumors of the uterine cervix and vagina did not
develop spontaneously in the mice (group 9). In all the
groups, unitary tumors of the lung and mammary gland
developed and these were characteristic of the spontaneous
tumor background of the mouse strain used (28). All three
ginseng drugs, by peroral administration, did not signifi-
cantly influence the incidence of uterine, cervical or vaginal
tumors (groups 2, 3 and 4). In the control group 5, DMBA
after co-treatment with tampons soaked with saline induced
uterine cervix and vagina tumors much faster than occurred
in the DMBA-only control group 1. This is probably linked
with tumor promotion by irritation and inflammatory reac-
tions of the cervix and vagina caused by daily intravaginal
applications of tampons (36). In comparison with the appro-
priate control group 5, bioginseng (group 6), panaxel (group
7) and panaxel-5 (group 8) applied topically significantly
decreased the total incidence of uterine, cervical and vaginal
tumors by 27.8%, 22.3% and 36.6%, respectively, and also
the incidence of carcinomas with these localizations by 25.0%,
30.8% and 35.6%, respectively. In conclusion, the ginseng
drugs effectively inhibited DMBA-induced uterine, cervical
and vaginal carcinogenesis only after intravaginal applica-
tions of ginseng drugs, whereas they did not significantly
influence the development of these tumors in mice treated
perorally.
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Treatment Group Number 
of rats Total Braina Spinal corda Peripheralb
nerves
Kidneyc Otherse
1 ENU only, 44 41 (93.2%) 36 (81.8%) 19 (43.2%) 9 (20.5%) 15 (34.1%) 1 (2.3%)
control 140 85 27 11 16 1
3.18±0.21 1.93±0.17 0.61±0.07 0.25±0.07 0.36±0.07 0.02±0.03
2 ENU+ 31 23 (74.2%)
f 18 (58.1%)f 8 (25.8%) 4 (12.9%) 7 (22.6%) 3 (9.7%)
bioginseng 56 31 9 4 9 3
1.81±0.18
g 1.00±0.13
g 0.29±0.09
g 0.13±0.05 0.29±0.09 0.10±0.05
3 ENU+ 38 34 (89.5%) 25 (65.8%) 14 (36.8%) 8 (21.1%) 6 (15.8%) 5 (13.2%)
panaxel 81 44 16 9 9 6
2.13±0.19
g 1.16±0.12
g 0.42±0.08 0.24±0.08 0.16±0.04 
g 0.16±0.08
4 ENU+ 32 28 (87.5%) 21 (65.6%) 12 (37.5%) 4 (12.5%) 9 (28.1%) 1 (3.1%)
panaxel-5 73 43 16 4 9 1
2.28±0.17
g 1.34±0.13
g 0.50±0.09 0.12±0.04 0.28±0.04 0.03±0.04
5 Intact control 30 4 (13.3%) 4 (13.3%)
5 5
0.17±0.08 0.17±0.08 
Table 2. Effects of the drugs of ginseng on the ENU-induced transplacental carcinogenesis in rats
aMainly oligodendrogliomas, mixed oligoastrocytomas, astrocytomas and, rarely, ependymomas, meningiomas and glioblastomas; bThe majority of
the tumors are malignant schwannomas, and in some cases mixed malignant tumors with both sarcomatous and neurogenic component; cThe most
of the tumors are mesenchymal, and in some cases epithelial adenocarcinomas; eUnitary adenomas of pituitary gland, leukemias, mammary adeno-
carcinomas and fibroadenomas, ovarian carcinomas, intestinal adenocarcinomas; fStatistically significant (p<0.05) compared to the control group
given ENU only by the chi-square test; 
gStatistically significant (p<0.05-0.001) compared to the control group given ENU only by the Student’ s t-test.
Tumor incidence, number of tumors and average number of tumors/rat (Mean±SD)
Group Treatment
Number 
of mice Total Carcinomas
a Papillomasb
Incidence of other 
tumors
c
1 DMBA only, control 38 26 (68.4%) 18 (47.4%) 8 (21.1%) 6 (15.8%)
2 DMBA+bioginseng p.o. 40 20 (50.0%) 15 (37.5%) 5 (12.5%) 3 (7.5%)
3 DMBA+panaxel p.o. 33 19 (57.6%) 13 (39.4%) 6 (18.2%) 3 (9.1%)
4 DMBA+panaxel-5 p.o. 35 22 (62.9%) 17 (48.6%) 5 (14.3%) 4 (11.4%)
5 DMBA+saline i.v., control 38 32 (84.2%) 28 (73.7%) 4 (10.5%) 2 (5.3%)
6 DMBA+bioginseng i.v. 39 22 (56.4%)d 19 (48.7%)d 3 (7.7%) 2 (5.1%)
7 DMBA+panaxel i.v. 21 13 (61.9%) 9 (42.9%)d 4 (19.0%) 1 (4.8%)
8 DMBA+panaxel-5 i.v. 21 10 (47.6%)d 8 (38.1%)d 2 (9.5%) 2 (9.5%)
9 Intact control 20 -- 3 (15.0%)
Table 3. Effects of the drugs of ginseng on DMBA-induced carcinogenesis of the cervix and vagina in female mice
p.o.-perorally; i.v.-intravaginally. aThe majority of the carcinomas are planocellular, and in some cases mixed adeno-planocellular carcinomas and
adenocarcinomas; 
bPlanocellular papillomas; cUnitary adenomas of the lung and adenocarcinomas of the mammary gland; dStatistically significant
(p<0.05-0.001) compared to the control group given DMBA and saline intravaginally by the chi-square test.
Incidence of the cervix and vagina tumorsStudy on the influence of the ginseng drugs on immu-
nological parameters
The results on the influence of the ginseng drugs on the
cytotoxic and growth-stimulating activities of macrophages
are summarized in Table 4. It was found that all three gin-
seng drugs induced a strong cytotoxic effect in macrophages
on the tumor cells. In comparison with the control, biogin-
seng, panaxel and panaxel-5 significantly inhibited the pro-
liferative activity of the P3X-63-Ag/8 tumor cells in cul-
ture by 58.5%, 65.5% and 58.5%, respectively. None of
the ginseng drugs enhanced the growth-stimulating activi-
ty of macrophages. Moreover, in this system the growth-
stimulating activity of macrophages was suppressed by the
drugs. Compared with the control, bioginseng significantly
suppressed the growth-stimulating activity of macrophages
only by 35.9%, and panaxel and panaxel-5 suppressed this
activity only by 15.5% and 12.6%, respectively, not signifi-
cantly.
The result on the influence of ginseng drugs on the func-
tional activity of T-lymphocytes in guinea pigs are present-
ed in Table 5. Cyclophosphamide produced T-immunodefi-
ciency in animals that showed significant decreases in the
numbers of E-rosettes (by 52.6%) and their absolute quan-
tity (by 54.9%) compared with the intact control. Compared
with the cyclophosphamide-only group, bioginseng and
panaxel significantly raised the relative amount of E-rosettes
by 29.9% and 50.2%, respectively, and their absolute quan-
tity by 40.0% and 42.6%, respectively.
Study on the effect of ginseng drugs on some hor-
monal parameters
The results of our study on the effect of the ginseng drugs
on the hormonal status of male rats are presented in Table 6.
All three ginseng drugs stimulated the production of thy-
roid hormones. Compared with the intact control, biogin-
seng, panaxel and panaxel-5 significantly raised the blood
plasma concentrations of thyroxine by 87.8%, 79.0% and
108.3% and of tri-iodothyronine by 36.1%, 23.6% and
27.8%, respectively. In addition, bioginseng increased the
concentration of thyroid-stimulating hormone by 14.5%
compared with the intact control group. All three ginseng
drugs had no significant influence upon the pituitary-adreno-
cortical system. The blood plasma levels of corticotropin,
aldosterone and corticosterone in all groups were similar.
The results of our study on the influence of the ginseng
drugs on estradiol blood plasma levels in female rats exposed
to MNU are presented in Table 7. The content of estradiol
in the blood of rats increased because of MNU influence.
Compared with the intact control, the level of estradiol in
blood from rats of the MNU-only group was elevated by
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In the table the data are presented on level of [H
3] thymidine incorpora-
tion into proliferating tumor target cells of line P3X-63-Ag/8. 
aStatistically
significant (p<0.001) compared to the control group by the Student’ s t-
test.
Group Number of mice
Cytotoxic activity,
impulses/hole of
plate, minute×
10
2, (Mean±SD)
Growth-stimulat-
ing activity,
impulses/hole of
plate, minute×
10
2, (Mean±SD)
Control 20 67.5±9.45 51.5±4.12
Bioginseng 20 28.0±3.08a 33.0±3.31a
Panaxel 20 23.3±2.56a 43.5±4.40
Panaxel-5 20 28.0±3.36a 45.0± 4.05
Table 4. Influence of the drugs of ginseng on cytotoxic and
growth-stimulating activities of macrophages in male mice
aStatistically significant (p<0.001) compared to the intact control group
by the Student’ s t-test; 
bStatistically significant (p<0.01-0.001) com-
pared to the cyclophosphamide-only group by the Student’ s t-test.
Group
Number of
guinea pigs
Relative
amount of E-
rosettes, %
(Mean±SD)
Absolute quantity of
E-rosettes, thou-
sands of cells/mg of
the thymus tissue,
(Mean±SD)
Intact control 9 59.3±0.8 266.2±1.9
Cyclophosphamide 8 28.1±1.7a 120.1±7.9a
only
Cyclophosphamide 8 36.5±2.3b 168.1±8.3b
+bioginseng
Cyclophosphamide 8 42.2±3.4b 171.3±9.5b
+panaxel
Table 5. Influence of the drugs of ginseng on functional activity
of T-lymphocytes in male guinea pigs
Hormone
Control (n=15) Bioginseng (n=12) Panaxel (n=12) Panaxel-5 (n=12)
Corticotropin, pg/mL 79.5±10.1 68.2±6.8 70.1±9.4 69.0±7.2
Aldosterone, pg/mL 81.6±8.3 79.1±14.1 86.3±12.6 73.4±8.5
Corticosterone, ng/mL 158.8±6.7 164.2±10.4 171.1±11.5 160.3±7.7
Thyroid-stimulating hormone,  U/mL 0.76±0.03 0.87±0.04a 0.75±0.03 0.78±0.10
Thyroxine (T4), nmol/L 43.3±4.5 81.3±8.0a 77.5±6.1a 90.2±7.4a
Tri-iodothyronine (T3), nmol/L 0.72±0.05 0.98±0.09a 0.89±0.0a 0.92±0.07a
Table 6. Influence of the drugs of ginseng on the blood plasma level of some hormones in male rats
n-number of rats. aStatistically significant (p<0.05-0.001) compared to the intact control group by the Student’ s t-test.
Blood plasma level of hormone in groups (Mean±SD)68.0%. The ginseng drugs reduced this increase in estradiol
in blood induced by MNU in rats. In particular, this decline
in the blood estradiol level was prominent in animals that
received MNU together with the ginseng drugs; these ani-
mals developed no tumors of the mammary gland, and should
be compared with the subgroup of rats with mammary
tumors exposed to MNU only. Bioginseng, panaxel and
panaxel-5 reduced the blood estradiol level by 22.1%, 40.9%
and 51.2%, respectively, in the MNU-treated rats without
mammary tumors.
Clinical trials of the ginseng drugs on patients with
precancerous lesions
Table 8 presents the results of a study on the influence of
panaxel on the endoscopic appearance of the esophageal
mucosa by esophagoscopy in patients suffering from chronic
erosive esophagitis. The results of repeated esophagoscopic
examinations revealed that complete regression of erosions
and inflammatory lesions of the esophageal mucosa was
found in 25 (39.1%) of 64 treated patients 1 month after
treatment with panaxel, 2 months after treatment in 10
(25.6%) of 39 treated patients, and 3 months after treatment
in 12 (41.1%) of 29 treated patients. In general, treatment
with panaxel for 1-3 months induced complete regression
of erosions and inflammatory lesions of the esophageal mucosa
in 47 (73.4%) of 64 treated patients. In the control group,
spontaneous complete regression of erosions and inflamma-
tory lesions of the esophageal mucosa was observed only in
3 (15.8%) of 19 patients after 3 months observation. The
difference between the two groups is statistically significant.
Therefore, we concluded that panaxel rendered a strong ther-
apeutic effect on the esophageal mucosa of patients with
chronic erosive esophagitis.
Table 9 lists the results of our study on the influence of
bioginseng on the histopathological features of the endometri-
um in patients with endometrium hyperplasia. The results
of histopathological examinations of the endometrium ob-
tained by repeated diagnostic curettages of the uterus demon-
strated that after 5-6 months of treatment with bioginseng
complete regression of the endometrial hyperplasia was found
in 3 (27.3%) of 11 treated patients. These three patients
with positive result after panaxel treatment had a diagnosis
of adenomatous-cystic hyperplasia prior to the start of the
treatment. Bioginseng had no therapeutic effect in patients
with atypical hyperplasia of the endometrium. Repeated
diagnostic curettages of the uterus and histopathological
examinations of the endometrium showed adenomatous-
cystic or atypical hyperplasia of the endometrium remained
in all 9 control patients 5-6 months after observation. The
difference between the two groups was not statistically sig-
nificant. Thus, long-term treatment with bioginseng seems
to regress adenomatous-cystic hyperplasia of the endometri-
um in some patients.
Assessment of toxicity
In our study, none of the ginseng drugs was observed to
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Group
The blood plasma level of estradiol, pmol/L
In all rats
In rats with mam-
mary tumors
In rats without
mammary tumors
n Mean±SD Mean±SD Mean±SD nn
Intact control 12 250±20
MNU only,  23 420±67a 17 389±49a 6 520±230 
control
MNU+ 18 370±50a 6 508±120a 12 303±70
bioginseng
MNU+ 21 270±34 7 340±49 14 230±33b
panaxel
MNU+ 21 310±49 10 440±91a 11 190±28b
panaxel-5
Table 7. Influence of the drugs of ginseng on the blood plasma
level of estradiol in female rats subjected to MNU
Group
Number
of
patients
Number of patients with
complete
regression of
erosions and
inflammatory
lesions
partial regres-
sion of erosions
and inflamma-
tory lesions
without
effect
Treatment by
panaxel for 64 47 (73.4%)a 13 (20.3%) 4 (6.3%)a
1-3 months
Control
patients after 19 3 (15.8%) 4 (21.1%) 12 (63.2%)
3 months of
observation
Table 8. Influence of panaxel on endoscopic appearance of
the esophageal mucosa in patients with chronic erosive eso-
phagitis
aStatistically not significant (p<0.1) compared to the group of control
patients which were not given any treatment by the chi-square test.
Group
Number of
patients
Number of patients with
complete regres-
sion of hyperplasia
without
effect
Treatment by bioginseng 
11 3 (27.3%)a 8 (72.7%) for 5-6 months
Control patients after 5-6
9 0 9 (100%) months of observation
Table 9. Influence of bioginseng on histologic appearance of
the endometrium in patients with the endometrium hyperplasia
n-number of rats. aStatistically significant (p<0.05-0.01) compared to
the intact control group by the Student’ s t-test; 
bStatistically significant
(p<0.01-0.001) compared to the MNU-only group, subgroup in rats
with mammary tumors, by the Student’ s t-test.
aStatistically significant (p<0.001) compared to the group of control
patients which were not given any treatment by the chi-square test.have a toxic effect on either rats or mice. All animals devel-
oped normally and there was no significant difference between
the body weights of treated and control animals. In clinical
trials patients treated with panaxel or bioginseng did not
develop any serious side effects. Two patients treated with
panaxel and one patient treated with bioginseng complained
of sleep disorders that were probably due to the tonic action
of the ginseng drugs.
DISCUSSION
Our experiments show for the first time that ginseng
drugs inhibit the development of tumors of the mammary
gland, nervous system, kidney, uterine cervix and vagina as
induced by chemical carcinogens in animals. All three gin-
seng drugs studied showed similar anticarcinogenic effects
in the carcinogenic models used. It is important to empha-
size that the ginseng drugs inhibited the development of
induced tumors of various histogenesis and localizations, such
as mammary adenocarcinomas and fibroadenomas, kidney
mesenchymal tumors, brain and spinal cord gliomas, uter-
ine cervix and vaginal planocellular carcinomas. When taken
together with other earlier reports (6-19), our results sug-
gest that the anticancerogenic action of ginseng is organ
non-specific. The results of epidemiological studies (20-22)
further confirm the belief that ginseng is capable of inhibit-
ing the development of malignant tumors of many different
types. In our experiments, the ginseng drugs were applied
in the carcinogenic post-initiation phase. Other authors (6-
19) have reported that they render an anticancerogenic action,
when applied during the carcinogenic post-initiation phase.
Apparently, ginseng is capable of inhibiting the promotion
phase of carcinogenesis and early tumor progression.
Ginseng contains a number of biologically active sub-
stances, such as triterpenoidal glycosides (ginsenosides),
phenolic compounds, sesquiterpenes, alkypyrazine deriva-
tives, neutral or acidic polysaccharides, polyacetylenes and
others (4). The identities of its chemical components respon-
sible for its primary anti-carcinogenic effects and their modes
of chemopreventive action are not precisely known. It is
believed likely that the anticarcinogenic effects of ginseng
are due to the cooperative action of biologically active sub-
stances and that the mechanisms of tumor development
inhibition are complex.
The influence of ginseng on immunity is probably impor-
tant in terms of its ability to inhibit carcinogenesis. In our
experiments, it was shown that the ginseng drugs stimulat-
ed some parts of the immune system. Bioginseng, panaxel
and panaxel-5 induced the cytotoxic action of macrophages
on the tumor cells, but did not enhance the growth-stimu-
lating activity of macrophages. It is also known that such
modulation of macrophage activity can suppress tumor
development (33). Bioginseng and panaxel also restored the
reduced activity of T-lymphocytes caused by cyclophos-
phamide in guinea pigs. The stimulatory effects of the gin-
seng drugs on the cytotoxic action of macrophages and T-
lymphocytes explain, at least in part, the ability of ginseng
to inhibit the promotion of carcinogenesis and an early stage
of tumor progression.
Other immunomodulatory mechanisms of ginseng extracts
or its active constituents in terms of its promotion of cancer
chemoprevention have been reported. Water extract of Panax
ginseng activated mouse natural killer cells in vitro (10), and
red ginseng extract returned natural killer cell activity to a
normal level after this was markedly depressed by injections
of urethane or benzo(a)pyrene in mice (37). Extracts of Panax
ginseng enhanced natural killer and the antibody-dependent
cell cytotoxicity of peripheral blood mononuclear cells iso-
lated from both normal human individuals and patients
with depressed cellular immunity (38). In addition, Panax
ginseng extracts activated the phagocytosis of peripheral blood
polymorphonuclear leucocytes in cows (39) and humans
(40), and acidic polysaccharides isolated from the root of
Panax ginseng showed remarkable reticuloendothelial sys-
tem-potentiating activity in a carbon clearance test (41).
Ginsenoside Rg1 from Panax ginseng was found to increase
the number of spleen plaque-forming cells, the number of
antigen-reactive T-cells elicited by sheep red cells in mice,
increased the splenocyte natural killer activity, and exerted a
direct mitogenic effect on microcultured thymus cells (42).
The influence of ginseng on the hormonal system also
could contribute to its ability to inhibit the development of
tumors. We demonstrated that bioginseng, panaxel and
panaxel-5 administered to male rats for 7 days considerably
stimulated the production of the thyroid hormones, thyrox-
ine and tri-iodothyronine. This mechanism may relate to the
anticarcinogenic action of ginseng, because it is known that
decreased thyroid hormone activity stimulates the develop-
ment of some tumors in humans and experimental animals
(43). In contrast to the above, however, the ginseng drugs
did not influence the pituitary-adrenocortical system in the
present study, and after 7-days of administration did not
influence the blood levels of corticotropin, aldosterone and
corticosterone in male rats. Our results are in disagreement
with a result that a single administration of ginseng to rats
is accompanied by an increase in the basal level of corti-
cotropin and corticosteroids, whereas the basal level of cor-
ticotropin and corticosteroids are unchanged after 7-days of
administration (44). The stimulation of corticosteroids pro-
duction should have a great impact on the adaptogenic and
the stress-protective actions of ginseng, but the activity of
corticotropin and corticosteroids reverts to the basal level
after the long-term administration of ginseng.
The present study shows that the blood level of estradiol
in female rats treated by MNU was significantly higher than
that of intact female rats. The fact that bioginseng, panaxel
and panaxel-5 reduced the MNU-induced level of estradiol
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the ginseng drugs in this carcinogenesis model. It is well
known that anti-estrogenic drugs are capable of inhibiting
mammary carcinogenesis and that they are applied for pro-
phylaxis and for the treatment of breast cancer (45). It is
also known that some plants contain phytoestrogens that
blockade estrogen receptors in target-tissues and prohibit
the development of estrogen-dependent tumors (46). Panax
quinquefolius root extract was reported to induce the expres-
sion of pS2, the estrogen-regulated gene, in MCF-7 breast
cancer cells (47). The phytoestrogenic potential of ginseng
may contribute to its inhibition of  the  development of
hormone-dependent tumors, such as mammary and en-
dometrium cancers.
Other mechanisms may also contribute to the anticar-
cinogenic action of ginseng. For example, ginseng has anti-
oxidant properties (48). Ginseng extracts scavenged hydrox-
yl radicals resulted from iron-mediated lipid peroxidation
(49). Ginsenosides Rb1 and Rg1 were found to inhibit the
lipid peroxidation of rat liver and brain microsomes, and
increase the activities of catalase and GSH peroxidase (50).
Panaxadiol ginsenosides extracted from Panax ginseng
increase the transcription of Cu/Zn superoxide dismutase
and catalase genes (51). In smokers treated with red gin-
seng, plasma antioxidant concentrations increased, while
their mean levels of oxidative DNA damage, 8-hydroxy-
deoxyguanosine, and carbonyl contents decreased (52). Gin-
seng ginsenosides have anti-inflammatory activity (53), and
are capable of inhibiting phosphodiesterase activity, elevat-
ing the intracellular level of cyclic AMP (54), and to induc-
ing the differentiation of tumor cells (55). In a recent study,
it was shown that the ginsenoside-Rs4, a new ginseng
saponin isolated from Panax ginseng, elevated the protein
levels of p53 and p21WAF1, which are associated with the
induction of apoptosis in SK-HEP-1 cells (56).
In our preliminary clinical trials, panaxel was found to
have therapeutic effects on the pathological lesions of the
esophageal mucosa in patients with chronic erosive esophagi-
tis. These patients lived in a region of the Republic of Uzbek-
istan with a high incidence of esophageal cancer; chronic
esophagitis is considered a precancerous lesion of the esoph-
agus (57). Bioginseng, the other ginseng drug, produced
complete regression of adenomatous-cystic hyperplasia of
the endometrium in a small number of patients; endometri-
al hyperplasia is regarded as a precancerous lesion of the
endometrium (58). The dynamics of precancerous lesions is
one of the surrogate end-point biomarkers in cancer chemo-
preventive studies (59). The results of our preliminary clini-
cal trials led us to believe that the ginseng drugs should be
further studied as agents for the chemoprevention of eso-
phageal cancer in regions of high cancer risk. Further study
of the influence of the ginseng drugs on precancerous lesions
of the endometrium is recommended.
Organic germanium compounds have been shown to have
anticarcinogenic properties in a rat multi-organ carcinogen-
esis model (60) and in 1,2-dimethylhydrazine-induced intesti-
nal carcinogenesis in rats (61). Organic germanium in trace
quantities has immuno-enhancing, free radical scavenging
and antitumor activities (62). We speculate that the biotech-
nological drugs of ginseng, containing organic germanium
compounds, panaxel and panaxel-5, have greater anticar-
cinogenic and immuno-stimulatory effects than bioginseng.
However, in all the experiments, the anticarcinogenic and
immuno-stimulatory actions of the three biotechnological
ginseng drugs were effectively equivalent.
In conclusion, the results of our study shows that biotech-
nological drugs from tissue cultures of Panax ginseng C.A.
Meyer, namely, bioginseng, panaxel and panaxel-5, have anti-
carcinogenic activity in different animal chemical carcino-
genesis models. The ability of the ginseng drugs to induce
the cytotoxic activity of macrophages, to stimulate reactive
T-cell immunity, and to improve the production of thyroid
hormones may constitute a mechanism of their cancer chemo-
preventive action. Organic germanium compounds in panax-
el and panaxel-5 did not possess more anticarcinogenic or
immuno-stimulatory effect than bioginseng. In preliminary
clinical trials, panaxel and bioginseng both regressed pre-
cancerous lesions in patients with chronic erosive esophagi-
tis and adenomatous-cystic hyperplasia of the endometri-
um. Therefore, we recommend that ginseng should be rec-
ognized as a very promising agent for cancer chemopreven-
tion. Based on the accumulated experimental, epidemiolog-
ical and clinical results on the cancer chemopreventive activi-
ty of ginseng extracts and its active constituents, we suggest
that long-term clinical intervention trials design to further
our knowledge of the cancer chemopreventive effects of gin-
seng should be undertaken.
ACKNOWLEDGMENTS
We would like to thank Dr Oleg F. Chepik of the Histo-
pathological Department of the N.N. Petrov Research Insti-
tute of Oncology for his analysis of histological preparations
and Ms Lyudmila V. Mironova for her technical assistance.
REFERENCES
1. Alexandrov VA, Bespalov VG. Preclinical and clinical study of
cancer chemopreventive agents. St. Petersburg: Esculap, 1997; 32
(in Russian).
2. Kelloff GJ. Perspectives on cancer chemoprevention research and
drug development. Adv Cancer Res 2000; 78: 199-334.
3. Bradlow HL, Telang NT, Sepkovic DW, Osborne MP. Phytochemi-
cals as modulators of cancer risk. Adv Exp Med Biol 1999; 472:
207-21.
4. Yun TK. Update from Asia. Asian studies on cancer chemopreven-
Chemoprevention of Cancer by Cultured Panax Ginseng Drugs S51tion. Bradlow HL, Fishman J, Osborne MP, editors, Cancer pre-
vention. Novel nutrient and pharmaceutical developments. Ann NY
Acad Sci 1999; 889: 157-92.
5. Yun TK. Experimental and epidemiological evidence of the cancer-
preventive effects of Panax ginseng C.A. Meyer. Nutr Rev 1996; 54:
S71-81.
6. Yun TK, Yun YS, Han IW. Anticarcinogenic effect of long-term
oral administration of red ginseng on newborn mice exposed to var-
ious chemical carcinogens. Cancer Detect Prev 1983; 6: 515-25.
7. Yun TK, Lee YS. Anticarcinogenic effect of ginseng powders depend-
ing on the types and ages using Yun’ s anticarcinogenicity test (I).
Korean J Ginseng Sci 1994; 18: 89-94.
8. Yun TK, Lee YS. Anticarcinogenic effect of ginseng extracts depend-
ing on the types and ages using Yun’ s anticarcinogenicity test (II).
Korean J Ginseng Sci 1994; 18: 160-4.
9. Yun TK, Kim SH, Lee YS. Trial of a new medium-term model using
benzo(a)pyrene induced lung tumor in newborn mice. Anticancer
Res 1995; 15: 839-45.
10. Yun YS, Lee YS, Jo SK, Jung IS. Inhibition of autochthonous tumor
by ethanol insoluble fraction from Panax ginseng as an immunomod-
ulator. Planta Med 1993; 59: 521-4.
11. Konoshima T, Takasaki M, Tokuda H. Anti-tumor-promoting activ-
ities of the roots of Panax notoginseng (1). Nature Med 1996; 50:
158-62.
12. Kim JP, Park JG, Lee MD, Han MD, Park ST, Lee BH, Jung SE.
Co-carcinogenic effects of several Korean foods on gastric cancer
induced by N-methyl-N ’ -nitro-N-nitrosoguanidine in rats. Jpn J
Surg 1985; 15: 427-37.
13. Wu XG, Zhu DH. Influence of ginseng upon the development of
liver cancer induced by diethylnitrosamine in rats. J Tongji Med
Univ 1990; 10: 141-5, 133.
14. Konoshima T, Takasaki M, Ichiishi E, Murakami T, Tokuda H,
Nishino H, Duc NM, Kasai R, Yamasaki K. Cancer chemopreven-
tive activity of majonoside-R2 from Vietnamese ginseng, Panax
vietnamensis. Cancer Lett 1999; 147: 11-6.
15. Xiaoguang C, Hongyan L, Xiaohong L, Zhaodi F, Yan L, Lihua T,
Rui H. Cancer chemopreventive and therapeutic activities of red
ginseng. J Ethnopharmacol 1998; 60: 71-8.
16. Konoshima T, Takasaki M, Tokuda H. Anti-carcinogenic activity of
the roots of Panax notoginseng. II. Biol Pharm Bull 1999; 22: 1150-2. 
17. Keum YS, Park KK, Lee JM, Chun KS, Park JH, Lee SK, Kwon H,
Surh YJ. Antioxidant and anti-tumor promoting activities of the
methanol extract of heat-processed ginseng. Cancer Lett 2000; 150:
41-8.
18. Konoshima T, Takasaki M, Tokuda H, Nishino H, Duc NM, Kasai
R, Yamasaki K. Anti-tumor-promoting activity of majonoside-R2
from Vietnamese ginseng, Panax vietnamensis Ha et Grushv. (I).
Biol Pharm Bull 1998; 21: 834-8.
19. Rhee YH, Ahn JH, Choe J, Kang KW, Joe C. Inhibition of mutage-
nesis and transformation by root extracts of Panax ginseng in vitro.
Planta Med 1991; 57: 125-8.
20. Yun TK, Choi SY. A case-control study of ginseng intake and can-
cer. Int J Epidemiol 1990; 19: 871-6.
21. Yun TK, Choi SY. Preventive effect of ginseng intake against vari-
ous human cancers: a case-control study on 1987 pairs. Cancer
Epidemiol Biomarkers Prev 1995; 4: 401-8.
22. Yun TK, Choi SY. Non-organ specific cancer prevention of ginseng:
a prospective study in Korea. Int J Epidemiol 1998; 27: 359-64.
23. Slepyan L, Jouravleva D, Galynkin V, Yakovlev G. Biotechnology
of ginseng tissue culure cells as a model for development of new
ginseng preparation. In: International Ginseng Conference, Gin-
seng: Its Sciences and Its Markets. Hong Kong, China, 1999; 52.
24. Bioginseng. Officinal Article 42-1890.89 on 21.04.89 (in Russian).
25. Panaxel. Officinal Article 42-3044-98 on 13.10.1998 (in Russian).
26. Slepyan L, Antan I, Phedorova V, Kudrina L, Vasil’ eva N. Strains
of ginseng and other araliaceae and their usage. In: Bailey WG,
Whitehead C, Proctor JTA, Kyle JT, editors. Proceedings of the
International Ginseng Conference-Vancouver 1994. Canada, Burn-
aby, British Columbia: Simon Fraser University, 1995; 116-9.
27. Anisimov VN, Pliss GB, Iogannsen MG, Popovich IG, Romanov
KP, Monakchov AS, Averyanova TK. Spontaneous tumors in out-
bred LIO rats. J Exp Clin Cancer Res 1989; 8: 254-62.
28. Anisimov VN, Loktionov AS, Khavinson VK, Morozov VG. Effect
of low-molecular-weight factors of thymus and pineal gland on life
span and spontaneous tumor development in female mice of differ-
ent age. Mech Ageing Dev 1989; 49: 245-57.
29. Bespalov VG, Petrov AS, Troyan DN, Alexandrov VA. Anticar-
cinogenic effect of theophylline on the development of induced
tumors in animals. Experim Oncol 1993; 15: 23-7(in Russian).
30. Alexandrov VA, Bespalov VG, Boone CW, Kelloff GJ, Malone
WF. Study of postnatal effects of chemopreventive agents on off-
spring of ethylnitrosourea-induced transplacental carcinogenesis in
rats. I. Influence of retinol acetate,  -tocopherol acetate, thiamine
chloride, sodium selenite, and  -difluoromethylornithine. Cancer
Lett 1991; 60: 177-84.
31. Turusov VS, Mohr U, editors. Pathology of tumours in laboratory
animals, Second edition, Volume 1, Tumours of the rat. IARC Sci
Publ No 99. Lyon, France: International Agency for Research on
Cancer, 1990; 748.
32. Turusov VS, Mohr U, editors. Pathology of tumours in laboratory
animals, Second edition, Volume 2, Tumours of the mouse. IARC
Sci Publ No 111. Lyon, France: International Agency for Research
on Cancer, 1994; 776.
33. Okulov VB, Voytenkov BO, Ushmorov AG, Polischuk ND, Gro-
mov SA. Growth-stimulating phase of macrophage response to
activation: the phenomenon and its implications for tumour growth
and immunotherapy. J Cancer Res Clin Oncol 1992; 118: 537-41.
34. Stadecker MJ, Bishop J, Wortis HH. Rosette formation by guinea
pigs thymocytes and thymus derived lymphocytes with rabbit red
blood cells. J Immunol 1974; 111: 1834-56.
35. Druckrey H, Preussmann R, Ivankovic S, Schmahl D. Organotrope
carcinogene Wirkungen bei 65 verschiedenen N-Nitroso-Verbindun-
gen an BD-Ratten. Z Krebsforsch 1967; 69: 103-201(in German).
36. Cerutti PA. Response modification creates promotability in multi-
stage carcinogenesis. Carcinogenesis 1988; 9: 519-26.
37. Yun YS, Moon HS, Oh YR, Jo SK, Kim YJ, Yun TK. Effect of red
ginseng on natural killer cell activity in mice with lung adenoma
induced by urethan and benzo(a)pyrene. Cancer Detect Prev Suppl
S52 V.G. Bespalov, V.A. Alexandrov, A.Y. Limarenko, et al.1987; 1: 301-9.
38. See DM, Broumand N, Sahl L, Tilles JG. In vitro effects of echi-
nacea and ginseng on natural killer and antibody-dependent cell
cytotoxicity in healthy subjects and chronic fatigue syndrome or
acquired immunodeficiency syndrome patients. Immunopharmacol-
ogy 1997; 35: 229-35.
39. Hu S, Concha C, Cooray R, Holmberg O. Ginseng-enhanced oxida-
tive and phagocytic activities of polymorphonuclear leucocytes from
bovine peripheral blood and stripping milk. Vet Res 1995; 26: 155-
61.
40. Scaglione F, Ferrara F, Dugnani S, Falchi M, Santoro G, Fraschini
F. Immunomodulatory effects of two extracts of Panax ginseng C.A.
Meyer. Drugs Exp Clin Res 1990; 16: 537-42.
41. Tomoda M, Hirabayashi K, Shimizu N, Gonda R, Ohara N, Takada
K. Characterization of two novel polysaccharides having immuno-
logical activities from the root of Panax ginseng. Biol Pharm Bull
1993; 16: 1087-90.
42. Kenarova B, Neychev H, Hadjiivanova C, Petkov VD. Immunomod-
ulating activity of ginsenoside Rg1 from Panax ginseng. Jpn J Phar-
macol 1990; 54: 447-54.
43. Rao GN. Influence of diet on tumors of hormonal tissues. Prog Clin
Biol Res 1996; 394: 41-56.
44. Filaretov AA, Bogdanova TS, Podvigina TT, Bodganov AI. Role of
pituitary-adrenocortical system in body adaptation abilities. Exp
Clin Endocrinol 1988; 92: 129-36.
45. Chlebowski RT, Collyar DE, Somerfield MR, Pfister DG. Ameri-
can Society of Clinical Oncology technology assessment on breast
cancer risk reduction strategies: tamoxifen and raloxifene. J Clin
Oncol 1999; 17: 1939-55.
46. Kurzer MS, Xu X. Dietary phytoestrogens. Annu Rev Nutr 1997;
17: 353-81.
47. Duda RB, Zhong Y, Navas V, Li MZ, Toy BR, Alavarez JG. Ameri-
can ginseng and breast cancer therapeutic agents synergistically
inhibit MCF-7 breast cancer cell growth. J Surg Oncol 1999; 72:
230-9.
48. Gillis CN. Panax ginseng pharmacology: a nitric oxide link? Biochem
Pharmacol 1997; 54: 1-8.
49. Zhang D, Yasuda T, Yu Y, Zheng P, Kawabata T, Ma Y, Okada S.
Ginseng extract scavenges hydroxyl radical and protects unsaturat-
ed fatty acids from decomposition caused by iron-mediated lipid
peroxidation. Free Radic Biol Med 1996; 20: 145-50.
50. Deng HL, Zhang JT. Anti-lipid peroxilative effect of ginsenoside
Rb1 and Rg1. Chin Med J Engl 1991; 104: 395-8.
51. Chang MS, Lee SG, Rho HM. Transcriptional activation of Cu/Zn
superoxide dismutase and catalase genes by panaxadiol ginseno-
sides extracted from Panax ginseng. Phytother Res 1999; 13: 641-4.
52. Lee BM, Lee SK, Kim HS. Inhibition of oxidative DNA damage, 8-
OHdG, and carbonyl contents in smokers treated with antioxidants
(vitamin E, vitamin C, beta-carotene and red ginseng). Cancer Lett
1998; 132: 219-27.
53. Matsuda H, Samukawa K, Kubo M. Anti-inflammatory activity of
ginsenoside Ro. Planta Med 1990; 56: 19-23.
54. Stancheva SL, Alova LG. Ginsenoside Rg1 inhibits the brain cAMP
phosphodiesterase activity in young and aged rats. Gen Pharmacol
1993; 24: 1459-62.
55. Lee YN, Lee HY, Chung HY, Kim SI, Lee SK, Park BC, Kim KW.
In vitro induction of differentiation by ginsenoides in F9 teratocar-
cinoma cells. Eur J Cancer 1996; 32A: 1420-8.
56. Kim SE, Lee YH, Park JH, Lee SK. Ginsenoside-Rs4, a new type of
ginseng saponin concurrently induces apoptosis and selectively ele-
vates protein levels of p53 and p21WAF1 in human hepatoma SK-
HEP-1 cells. Eur J Cancer 1999; 35: 507-11.
57. Kavin H, Yaremko L, Valaitis J, Chowdhury L. Chronic esophagi-
tis evolving to verrucous squamous cell carcinoma: possible role of
exogenous chemical carcinogens. Gastroenterology 1996; 110:
904-14.
58. Burke TW, Tortolero-Luna G, Malpica A, Baker VV, Whittaker L,
Johnson E, Follen-Mitchell M. Endometrial hyperplasia and
endometrial cancer. Obstet Gynecol Clin North Am 1996; 23: 411-
56.
59. Kelloff GJ, Sigman CC, Hawk ET, Johnson KM, Crowell JA, Guy-
ton KZ. Surrogate end-point biomarkers in chemopreventive drug
development. In: Miller AB, Bartsch H, Boffetta P, Dragsted L,
Vainio H, editors, Biomarkers in cancer chemoprevention. IARC
Sci Publ No 154. Lyon: International Agency for Research on Can-
cer, 2001; 154: 13-26.
60. Jang JJ, Cho KJ, Lee YS, Bae JH. Modifying responses of allyl sul-
fide, indole-3-carbinol and germanium in a rat multi-organ car-
cinogenesis model. Carcinogenesis 1991; 2: 691-5.
61. Jao SW, Lee W, Ho YS. Effect of germanium on 1,2-dimethylhy-
drazine-induced intestinal cancer in rats. Dis Colon Rectum 1990;
33: 99-104.
62. Goodman S. Therapeutic effects of organic germanium. Med
Hypotheses 1988; 26: 207-15.
Chemoprevention of Cancer by Cultured Panax Ginseng Drugs S53